Droxidopa is a medication used to treat symptomatic neurogenic orthostatic hypotension (nOH) caused by dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy and primary autonomic failure caused by conditions such as Parkinson's disease. Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism.
- Mechanism
- Curator reviewed
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
- Primary indication
- For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease.Curator reviewed · 5 structured indications
- Formula / weight
- C9H11NO5 · 213.189 g/mol (avg)
- First approval
- United States, 2014
- Also known as
- DOPS · L-Dihydroxyphenylserine · L-DOPS · L-threo-dihydroxyphenylserine
- Code names
- SM-5688
- Brand names
Resolves to
QXWYKJLNLSIPIN-JGVFFNPUSA-NSMILESN[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=OWhat you can answer from here — as of January 07, 2021
Which drugs share a target with Droxidopa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account